Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2368]

New ibrutinib combination regimen shows substantial benefits in relapsed...

Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )

Obinutuzumab doubles remission duration in patients with relapsed, indolent non...

Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )

Pembrolizumab for head and neck cancer

Dr Tanguy Seiwert - University of Chicago, Chicago, USA

Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )

Pembrolizumab shows promising activity against head and neck cancer

Dr Tanguy Seiwert - University of Chicago, Chicago, USA

Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )

Prostate cancer and pharmacokinetics: Expert discussion

Prof Axel S. Merseburger and Prof Romano Danesi

Prostate cancer and pharmacokinetics: Expert discussion ( Prof Axel S. Merseburger and Prof Romano Danesi )

WIN 2015 hosts 'world class leaders' in personalised therapy

Prof Waun Ki Hong - University of Texas MD Anderson Cancer Center, Houston, USA

WIN 2015 hosts 'world class leaders' in personalised therapy ( Prof Waun Ki Hong - University of Texas MD Anderson Cancer Center, Houston, USA )

WIN 2015: Oncologists and industry working together for personalised medicine

Prof Razelle Kurzrock - University of California, San Diego, USA

WIN 2015: Oncologists and industry working together for personalised medicine ( Prof Razelle Kurzrock - University of California, San Diego, USA )

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Metastatic triple-negative breast cancer responds to immunotherapy ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

Real-world targeted treatment based on whole genome sequencing difficult in...

Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst...

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer ( Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst, Australia )

PARP inhibitor combo shows early promise for patients with and without BRCA...

Dr Timothy Yap - Royal Marsden Hospital, London, UK

PARP inhibitor combo shows early promise for patients with and without BRCA mutations ( Dr Timothy Yap - Royal Marsden Hospital, London, UK )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

Investigational ER degrader safe, with early signs of antitumour activity...

Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA

Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer ( Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer